07/704565

SA

ABSTRACT OF THE DISCLOSURE

The present invention is directed to 5-HT_3 receptor antagonist compounds of formula I:



I

in which
the dashed line denotes an optional double bond;
n is 1, 2 or 3;
p is 0, 1, 2 or 3;
q is 0, 1 or 2;
each R^1 is independently selected from halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, amino carbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino;
each R^2 is lower alkyl; and

R^3 is a group selected from Formulae (a), (b), (c) and (d):


(a)


(b)


(c)


(d)

in which

u is 0 or 1;

z is 1, 2 or 3; and

R^4 is C_{1-7} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl-C_{1-2} alkyl, or a group $(CH_2)_tR^5$ where t is 1 or 2 and R^5 is thienyl, pyrrolyl, or furyl, each optionally further substituted by one or two substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C_{1-4} alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C_{1-4} alkyl optionally substituted by hydroxy, C_{1-4} alkoxy, carboxy, esterified carboxy or *in vivo* hydrolyzable acyloxy; and the pharmaceutically acceptable salts, individual isomers, mixtures of isomers, processes for preparation, compositions, and methods of use thereof.